Revenue Recognition

6 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition

4. Revenue Recognition

Revenue Disaggregation

The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only):

Net Revenues by Reportable Segment & Geographic Region

	Three Months Ended March 31,							Six Months Ended March 31,
	2022		2021		Inc (Dec)			2022		2021		Inc (Dec)
Diagnostics-
Americas	$	33,551	$	25,290		33	%	$	60,164	$	48,824		23	%
EMEA		7,113		6,071		17	%		13,206		12,101		9	%
ROW		439		588		(25	)%		937		1,345		(30	)%
Total Diagnostics		41,103		31,949		29	%		74,307		62,270		19	%
Life Science-
Americas		10,377		13,550		(23	)%		18,514		32,296		(43	)%
EMEA		33,246		21,773		53	%		61,894		54,066		14	%
ROW		26,505		17,992		47	%		44,857		29,549		52	%
Total Life Science		70,128		53,315		32	%		125,265		115,911		8	%
Consolidated	$	111,231	$	85,264		30	%	$	199,572	$	178,181		12	%

Net Revenues by Product Platform/Type

	Three Months Ended March 31,							Six Months Ended March 31,
	2022		2021		Inc (Dec)			2022		2021		Inc (Dec)
Diagnostics-
Molecular assays	$	4,385	$	4,395		—	%	$	9,137	$	8,985		2	%
Non-molecular assays		36,718		27,554		33	%		65,170		53,285		22	%
Total Diagnostics		41,103		31,949		29	%		74,307		62,270		19	%
Life Science-
Molecular reagents		40,334		37,752		7	%		71,822		83,776		(14	)%
Immunological reagents		29,794		15,563		91	%		53,443		32,135		66	%
Total Life Science		70,128		53,315		32	%		125,265		115,911		8	%
Consolidated	$	111,231	$	85,264		30	%	$	199,572	$	178,181		12	%

Net Revenues by Disease State (Diagnostics segment only)

	Three Months Ended March 31,							Six Months Ended March 31,
	2022		2021		Inc (Dec)			2022		2021		Inc (Dec)
Diagnostics-
Gastrointestinal assays	$	20,281	$	15,666		29	%	$	41,900	$	31,118		35	%
Respiratory illness assays		9,491		3,686		157	%		15,871		8,492		87	%
Blood chemistry assays		3,425		4,358		(21	)%		3,503		8,753		(60	)%
Other		7,906		8,239		(4	)%		13,033		13,907		(6	)%
Total Diagnostics	$	41,103	$	31,949		29	%	$	74,307	$	62,270		19	%

Royalty Income

Royalty income received from a third party related to sales of H. pylori products, totaled approximately $2,580 and $2,850 in the three months ended March 31, 2022 and 2021, respectively, and $3,550 and $3,710 in the six months ended March 31, 2022 and 2021, respectively. Royalty income is included as part of Non-molecular assays and Other within the Net Revenues by Product Platform/Type and Net Revenues by Disease State tables, respectively, above. 

Reagent Rental Arrangements

Revenue allocated to the lease elements of Reagent Rental arrangements totaled approximately $970 and $900 in the three months ended March 31, 2022 and 2021, respectively, and $1,725 and $1,780 in the six months ended March 31, 2022 and 2021, respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.